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   LETTERS TO THE EDITOR
doi:10.1002/ejhf.1 18 4
    Online publish-ahead-of-print Apr il 20201
  Urinar y sodium evaluation:
   the missing target for
 diuretic treatment
   optimization in acute heart
  failure patients? Letter
   regarding the article ‘Clinical
  importance of urinar y
   sodium excretion in acute
 heart failure’
       We read with interest the paper by Damman
 et al. 1 describing the clinical importance of
      early urinary sodium (uNa) excretion in acute
      heart failure (AHF) patients. We fully agree
      with the potential interest of uNa moni-
       toring in this context. The strength of uNa
       excretion could be its ability to combine, in
      a single parameter, urinary volume and spot
    sodium concentration, both target criteria
  suggested by the Heart Failure Association
    therapeutic algorithm of congestive AHF.2
      Moreover, it seems to perform even better
      as a prognostic predictor than these two
  indicators considered separately.
     However, we have some comments on
      the paper. The observational design and the
      absence of a prospective protocol led to
    signicant potential biases. For example, an
      appraisal of the congestion status at presen-
      tation is lacking: an objective evaluation (i.e.
 “wet score”3       ) may allow for a more genuine
    interpretation of the uNa-independent prog-
      nostic role. In fact, admitted patients, depend-
       ing on their congestion grade and on doses
     and timing of intravenous diuretic administra-
     tion in the emergency department, may be
      in a different position in the time-natriuresis
      curve. Another interesting point to be eluci-
      dated is whether uNa maintains its predictive
     role irrespective of baseline ejection fraction
     and the use of inotropes/vasopressors, which
  was not standardized.
    Nevertheless, the way through which
     this parameter would affect mortality with-
      out a solid correlation with heart failure
rehospitalizations remains unclear. It would
     therefore be interesting to evaluate the
       association of 6 h uNa excretion with other
     surrogated endpoints, such as the incidence
     of treatment failure, worsening renal function
     (WRF) or changes in N-terminal pro-B-type
     natriuretic peptide (NT-proBNP). In a recent
     sub-analysis of the DRAIN randomized con-
     trolled trial, we demonstrated the association
      between low early uNa spot and worse
     diuretic response in patients admitted for
 acute decompensation of advanced chronic
       heart failure with a high risk of diuretic
resistance.4,5      Early spot uNa 50mmol/L was
     associated with higher levels of NT-proBNP
        and a higher incidence of WRF at 72 h,
     suggesting worse unloading of these patients
    after a standardized therapeutic protocol.
       In conclusion, even if we agree on the
    appealing idea of uNa as a single, low-cost
   and precocious indicator of AHF outcome,
       caution must be taken in the interpretation of
      this value, which needs to be contextualized
    in a global clinical assessment. Prospective
     randomized studies are needed to elucidate
      if natriuresis only represents a predictor of
     diuretic response and, eventually, a prognos-
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  Urinar y sodium evaluation:
   the missing target for
 diuretic treatment
   optimization in acute heart
  failure patients? Reply
       Dr Galluzzo et al. commented on our manu-
      script on urinary sodium content after diuretic
    initiation in acute heart failure (HF).1 They
     expressed their concerns on the absence
       of a prospective protocol and the fact that
      there was no estimate of congestion (score)
     available. The Authors suggest that given
   these limitations, patients could have been
      presenting at different positions at the ‘time-
    natriuresis’ curve. Certainly, we acknowledge
  that the observational nature of our study
  is a limitation.1    However, our ndings are
     a reection of ‘real-world’ data, which also
      inherently means that there was no structural
       scoring of congestion at start of treatment. It
       is also important to realize that our primary
    ndings were based on 6 h urinary sodium
    content. Although many patients improve
      clinically during the rst hours of treatment,
    it is not likely assessment of congestion at
     baseline would have altered our ndings at
        6 h. We did show that patients who had
       lower urinary sodium content at 6 h had
      evidence of more severe HF with higher
   natriuretic peptide levels at baseline, lower
     blood pressure, worse renal function, more
       frequent use of loop diuretics at baseline and
     more use of inotropes and vasopressors.
     © 2020 European Society of Cardiology
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    1934 Letters to the Editor
      The Authors point to their subanalysis of
       the small DRAIN study in 80 patients, where
       they evaluated early (2 h) spot urinary sodium
     content and surrogateoutcome measures and
      found similar results as compared with our
analyses.2     Our results should be interpreted
    slightly different, considering we evaluated
       total urinary sodium content over 6 h, which
      is probably a better representation of total
      natriuretic response to a given diuretic dose
   than spot urinary sodium.3–5  With regard
    to the inotrope/vasopressor regimen not
  being standardized in our cohort, we con-
 sider these therapies only in very selected
     patients, according to the European Society
      of Cardiology HF guidelines, where they are
       only advocated in a small proportion of acute
    HF patients with severe hypotension.6  In our
     study, the prognostic information of urinary
       sodium content at 6 h was unchanged by
    adjusting for inotrope/vasopressor use [haz-
      ard ratio (HR) 1.05, 95% condence interval
       (CI) .01 1 1– .08, 0.008, perP = 10mmol
       decrease (n = 146)] or left ventricular ejec-
      tion fraction [(HR .01.05, 95% CI 1 1 1– .08,
         P n= 0.003, per 10mmol decrease ( = 157)].
      Change in natriuretic peptide level was only
         available in a subset of patients at 24 h after
   admission, and was not different in tertiles
          of urinary sodium (P = 0.69 and P = 0.67 for
    absolute and relative change, respectively).
  We do not think worsening renal func-
    tion (WRF), as used by the Authors, is an
    appropriate surrogate endpoint in acute
    HF patients without considering natri-
   uretic/diuretic response. WRF in a patient
       with good natriuresis is not true WRF and
     should be termed pseudo-WRF, and cannot
      directly be compared with WRF in patients
   with poor natriuresis/diuretic response,
     according to most recent position papers
      on how to evaluate renal function in HF.7,8
   For instance, in our cohort and using dif-
    ferent denitions, WRF was consistently
   more frequent in patients with the highest
       urinary sodium content at 6 h. Yet, the
    prognostic information of urinary sodium
        at 6 h was unaffected by the occurrence of
      WRF, and WRF itself was not independently
     associated with clinical outcome. This again
     highlights not to use serum creatinine/WRF
      as a response marker during decongestion in
 acute HF.
      Finally, the nding that urinary sodium con-
        tent at 6 h was only associated with all-cause
      mortality and appeared not to be associated
      with HF readmission is probably related to
         the severity of HF in our tertiary HF clinic, as
       well as a tendency of some elderly patients
          with HF at our clinic to decide not to be read-
mitted after discharge as part of advanced
     care planning. Therefore, we also evaluated
      the combined endpoint of mortality and HF
   rehospitalization, conrming our primary
      results. We agree with the Authors that
     we need prospective randomized studies to
      evaluate whether this cheap and easy marker
     of natriuretic/diuretic response is a valuable
       tool to assess treatment effect or can serve
      as therapeutic target in a cute HF.
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    Effects of vericiguat in heart
   failure with reduced ejection
    fraction: do not forget sST2.
   Letter regarding the article
   ‘Baseline features of the
 VICTORIA (Vericiguat
    Global Study in Subjects with
   Heart Failure with Reduced
  Ejection Fraction) trial’
We read with interest the paper by Pieske
 et al.1    describing the baseline characteristics
      of patients enrolled in the VICTORIA (Veri-
  ciguat Global Study in Subjects with Heart
     Failure with Reduced Ejection Fraction) trial.
    Despite the quite extensive description of
   patient characteristics at baseline, no infor-
     mation about heart failure (HF) biomarkers
other than natriuretic peptides is available.
    Specically, data about high-sensitivity cardiac
 troponin T (hs-cTnT) and soluble suppres-
     sion of tumorigenesis-2 (sST2) have not
    been provided, although these biomarkers
    yield strong and independent prognostic
signicance beyond natriuretic peptides for
     the prediction of all-cause and cardiovascular
   mortality and HF hospitalization in patients
     with chronic HF, particularly those with
    HF and reduced ejection fraction (HFrEF).
       While hs-cTnT will be analysed in a planned
      post-hoc analysis of the VICTORIA trial, sST2
apparently will not.2  This attitude of study
investigators may be related to the results
   of the SOCRATES-PRESERVED (Soluble
     Guanylate Cyclase Stimulator in Heart Failure
    Patients with Preserved Ejection Fraction)
     trial, where no change in sST2 levels was
       observed, although this was in line with the
      overall trend of other cardiac biomarkers in
    this study population, including natriuretic
peptides.3   Conversely, sST2 was not evalu-
    ated in the SOCRATES-REDUCED (Soluble
     © 2020 European Society of Cardiology
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